Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 11/2015

Open Access 01-11-2015 | Original Article

Low serum hyaluronic acid levels associated with spontaneous HBsAg clearance

Authors: S. Harkisoen, J. E. Arends, A. van den Hoek, K. J. van Erpecum, G. J. Boland, A. I. M. Hoepelman

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 11/2015

Login to get access

Abstract

Purpose

The pathophysiological underlying mechanism of spontaneous HBsAg clearance in hepatitis B virus (HBV) infected patients is largely unknown. However, serum hyaluronic acid (sHA) plays a role in liver fibrosis progression and reversely could serve as a potential biomarker for HBsAg clearance. This study investigates whether low sHA is associated with HBsAg loss in non-Asian HBV patients.

Methods

Non-Asian women living in Amsterdam with known chronic HBV infection between 1990–2003 were invited for a single follow-up visit at the Municipal Health Service Amsterdam between September 2011 to May 2012. Serum hyaluronic acid and liver stiffness measurement together with clinical evaluation, biochemical and virologic blood tests were performed.

Results

Of the 160 women, HBsAg loss occurred in 38 (23 %) patients between diagnosis and follow-up. sHA levels were lower in HBsAg negative patients compared to HBsAg positive patients (14.5 [9.4–27.2] ng/mL vs 25.0 [12.3–42.5] ng/mL, p <0.01). A similar distinction in sHA between low and high HBV DNA was noted. sHA had a significant discriminatory ability to differentiate between HBsAg positive and HBsAg negative patients, (AUC 0.65 [95 % CI 0.55–0.75], p < 0.01). In multivariable analysis only sHA level was associated with HBsAg loss (OR 0.4 [0.2–0.9]). Finally, F3-F4 fibrosis (cut-off >8.1 kPa) was diagnosed in 3 % in HBsAg negative patients compared to 10 % in HBsAg positive patients (p = 0.15).

Conclusion

Serum HA levels are lower in patients who experience spontaneous HBsAg loss compared to HBsAg positive patients.
Literature
3.
go back to reference Istaces N, Gulbis B (2015) Study of FibroTest and hyaluronic acid biological variation in healthy volunteers and comparison of serum hyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals. Clin Biochem 48(10–11):652–657. doi:10.1016/j.clinbiochem.2015.03.020 CrossRefPubMed Istaces N, Gulbis B (2015) Study of FibroTest and hyaluronic acid biological variation in healthy volunteers and comparison of serum hyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals. Clin Biochem 48(10–11):652–657. doi:10.​1016/​j.​clinbiochem.​2015.​03.​020 CrossRefPubMed
4.
go back to reference Silva MB, Silva MG, Shinjo SK (2014) Serum hyaluronic acid in polymyositis: high serum levels tend to correlate with disease activity. Acta Reumatologica Portuguesa 39(3):248–253PubMed Silva MB, Silva MG, Shinjo SK (2014) Serum hyaluronic acid in polymyositis: high serum levels tend to correlate with disease activity. Acta Reumatologica Portuguesa 39(3):248–253PubMed
5.
go back to reference Ramadori G, Zohrens G, Manns M, Rieder H, Dienes HP, Hess G, Meyer KH, Buschenfelde Z (1991) Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity. Eur J Clin Invest 21(3):323–330CrossRefPubMed Ramadori G, Zohrens G, Manns M, Rieder H, Dienes HP, Hess G, Meyer KH, Buschenfelde Z (1991) Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity. Eur J Clin Invest 21(3):323–330CrossRefPubMed
6.
go back to reference Guechot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R (1994) Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 20(3):388–393CrossRefPubMed Guechot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R (1994) Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 20(3):388–393CrossRefPubMed
7.
go back to reference Guechot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R (1995) Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol 22(1):22–26CrossRefPubMed Guechot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R (1995) Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol 22(1):22–26CrossRefPubMed
8.
go back to reference Montazeri G, Estakhri A, Mohamadnejad M, Nouri N, Montazeri F, Mohammadkani A, Derakhshan MH, Zamani F, Samiee S, Malekzadeh R (2005) Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 5:32. doi:10.1186/1471-230X-5-32 PubMedCentralCrossRefPubMed Montazeri G, Estakhri A, Mohamadnejad M, Nouri N, Montazeri F, Mohammadkani A, Derakhshan MH, Zamani F, Samiee S, Malekzadeh R (2005) Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 5:32. doi:10.​1186/​1471-230X-5-32 PubMedCentralCrossRefPubMed
10.
go back to reference van Hattum J, van Oudenaren A, Schalm SW, Visser JW, Benner R (1984) T-lymphocyte subpopulations in patients with various courses after hepatitis B virus infection. Scand J Gastroenterol 19(4):497–501PubMed van Hattum J, van Oudenaren A, Schalm SW, Visser JW, Benner R (1984) T-lymphocyte subpopulations in patients with various courses after hepatitis B virus infection. Scand J Gastroenterol 19(4):497–501PubMed
12.
go back to reference Ahn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, Han KH, Park C, Moon YM, Chon CY (2005) Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 42(2):188–194. doi:10.1016/j.jhep.2004.10.026 CrossRefPubMed Ahn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, Han KH, Park C, Moon YM, Chon CY (2005) Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 42(2):188–194. doi:10.​1016/​j.​jhep.​2004.​10.​026 CrossRefPubMed
13.
go back to reference Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H (2006) Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 119(1):71 e79–16. doi:10.1016/j.amjmed.2005.02.033 CrossRef Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H (2006) Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 119(1):71 e79–16. doi:10.​1016/​j.​amjmed.​2005.​02.​033 CrossRef
14.
go back to reference Harkisoen S, Arends JE, van den Hoek JA, Whelan J, van Erpecum KJ, Boland GJ, Hoepelman AI (2014) Historic and current hepatitis B viral DNA and quantitative HBsAg level are not associated with cirrhosis in non-Asian women with chronic hepatitis B. Int J Infect Dis 29:133–138. doi:10.1016/j.ijid.2014.08.005 CrossRefPubMed Harkisoen S, Arends JE, van den Hoek JA, Whelan J, van Erpecum KJ, Boland GJ, Hoepelman AI (2014) Historic and current hepatitis B viral DNA and quantitative HBsAg level are not associated with cirrhosis in non-Asian women with chronic hepatitis B. Int J Infect Dis 29:133–138. doi:10.​1016/​j.​ijid.​2014.​08.​005 CrossRefPubMed
17.
go back to reference Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29(12):1705–1713CrossRefPubMed Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29(12):1705–1713CrossRefPubMed
18.
go back to reference Cardoso AC, Carvalho-Filho RJ, Stern C, Dipumpo A, Giuily N, Ripault MP, Asselah T, Boyer N, Lada O, Castelnau C, Martinot-Peignoux M, Valla DC, Bedossa P, Marcellin P (2012) Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int 32(4):612–621. doi:10.1111/j.1478-3231.2011.02660.x CrossRefPubMed Cardoso AC, Carvalho-Filho RJ, Stern C, Dipumpo A, Giuily N, Ripault MP, Asselah T, Boyer N, Lada O, Castelnau C, Martinot-Peignoux M, Valla DC, Bedossa P, Marcellin P (2012) Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int 32(4):612–621. doi:10.​1111/​j.​1478-3231.​2011.​02660.​x CrossRefPubMed
20.
go back to reference Bollyky PL, Falk BA, Long SA, Preisinger A, Braun KR, Wu RP, Evanko SP, Buckner JH, Wight TN, Nepom GT (2009) CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta. J Immunol 183(4):2232–2241. doi:10.4049/jimmunol.0900191 PubMedCentralCrossRefPubMed Bollyky PL, Falk BA, Long SA, Preisinger A, Braun KR, Wu RP, Evanko SP, Buckner JH, Wight TN, Nepom GT (2009) CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta. J Immunol 183(4):2232–2241. doi:10.​4049/​jimmunol.​0900191 PubMedCentralCrossRefPubMed
22.
24.
go back to reference Pontinha N, Pessegueiro H, Barros H (1999) Serum hyaluronan as a marker of liver fibrosis in asymptomatic chronic viral hepatitis B. Scand J Clin Lab Invest 59(5):343–347CrossRefPubMed Pontinha N, Pessegueiro H, Barros H (1999) Serum hyaluronan as a marker of liver fibrosis in asymptomatic chronic viral hepatitis B. Scand J Clin Lab Invest 59(5):343–347CrossRefPubMed
25.
go back to reference Zhang YX, Wu WJ, Zhang YZ, Feng YL, Zhou XX, Pan Q (2008) Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B. World J Gastroenterol 14(46):7117–7121PubMedCentralCrossRefPubMed Zhang YX, Wu WJ, Zhang YZ, Feng YL, Zhou XX, Pan Q (2008) Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B. World J Gastroenterol 14(46):7117–7121PubMedCentralCrossRefPubMed
27.
go back to reference Parsian H, Rahimipour A, Nouri M, Somi MH, Qujeq D (2010) Assessment of liver fibrosis development in chronic hepatitis B patients by serum hyaluronic acid and laminin levels. Acta Clin Croat 49(3):257–265PubMed Parsian H, Rahimipour A, Nouri M, Somi MH, Qujeq D (2010) Assessment of liver fibrosis development in chronic hepatitis B patients by serum hyaluronic acid and laminin levels. Acta Clin Croat 49(3):257–265PubMed
28.
go back to reference Li F, Zhu CL, Zhang H, Huang H, Wei Q, Zhu X, Cheng XY (2012) Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B. Braz J Infect Dis 16(1):9–14CrossRefPubMed Li F, Zhu CL, Zhang H, Huang H, Wei Q, Zhu X, Cheng XY (2012) Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B. Braz J Infect Dis 16(1):9–14CrossRefPubMed
29.
go back to reference Trembling PM, Lampertico P, Parkes J, Tanwar S, Vigano M, Facchetti F, Colombo M, Rosenberg WM (2014) Performance of enhanced liver fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 21(6):430–438. doi:10.1111/jvh.12161 PubMedCentralCrossRefPubMed Trembling PM, Lampertico P, Parkes J, Tanwar S, Vigano M, Facchetti F, Colombo M, Rosenberg WM (2014) Performance of enhanced liver fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 21(6):430–438. doi:10.​1111/​jvh.​12161 PubMedCentralCrossRefPubMed
31.
go back to reference Kim BK, Kim HS, Yoo EJ, Oh EJ, Park JY, Kim do Y, Ahn SH, Han KH, Kim SU, Park YN (2014) Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. Hepatology 60(6):1911–1919. doi:10.1002/hep.27389 CrossRefPubMed Kim BK, Kim HS, Yoo EJ, Oh EJ, Park JY, Kim do Y, Ahn SH, Han KH, Kim SU, Park YN (2014) Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. Hepatology 60(6):1911–1919. doi:10.​1002/​hep.​27389 CrossRefPubMed
Metadata
Title
Low serum hyaluronic acid levels associated with spontaneous HBsAg clearance
Authors
S. Harkisoen
J. E. Arends
A. van den Hoek
K. J. van Erpecum
G. J. Boland
A. I. M. Hoepelman
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 11/2015
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-015-2467-x

Other articles of this Issue 11/2015

European Journal of Clinical Microbiology & Infectious Diseases 11/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.